Events

Apollo Therapeutics will be attending the Society for Investigative Dermatology (SID) Annual Meeting, taking place May 13 – 16 in Chicago.

On Thursday 14 May, our Chief Medical Officer, Sanjay Aggarwal, will present new data from the phase 2a study of camoteskimab, our anti‑IL‑18 monoclonal antibody. The presentation will highlight emerging insights from this program and its potential for the treatment of atopic dermatitis.

We look forward to engaging with colleagues across the dermatology community at SID.